This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.






Figure 3

F Tim Home	m Assault GE G 23hi 19455540 svisin Eissvisi / Page ee (1997)	
erarchy.		
RO Any CRO Name Sponsor Any Pharmaceutical Name Product COPD New Drug		
Project Primary Indication Trial Phase III No. 1		
Country England Centre East Anglia No.1	C S (Please Istlany significant medical history concomitant diseases (not related to trial indication)).	
Subject GFG 23111945/54 Visit First Visit Page History	i History of diagnosis	
T BOOK THE STATE OF THE STATE O	Use precise medical terminology) (asy month year) (if (Circle appropriate code)) (if none enter-none)	
	5.	
A WOOTEN		
iniod		
O Any CRO Name onsor Any Pharmaceutical Name		* 1
oduct COPD New Drug Dject Primary Indication al Phase III No. 1		
untry England ntre East Anglia No.1		
bject GFG 23111945/54 it First Visit		
ge History		
/ersional of to Prev Next Dutes Ociete	Submit Submit	
Know Panes	LY6-	
LERVE EVILL CERE LOST EVALUATION		
En LU PIGH NAT AOK MOK		
dy Down Next AutoNext	Local time Tue May 15 \ 5.52.37.200 UBST	Professional Company of the Company
The second se	The results treated that the result of the results and the results are results and the results	302.433

cd- dev3- a- 56

Figure 5

1/4 2/4 1/2 3/4 2/2 4/4 P2 **V**2 S1 1/2 2/2 SUBJECTS **PAGES** VISITS

1/1

Figure 4

= AUDIT NODE

=TAG NODE



HISON BACK FOWARD	<u>伊夏尚</u> frial "phase III no 1"	Live Report trial "phase 1111 no. 1" Level Totals Constructs	or 0 Centre 4 Page ct 0 Subject 8 Script Scr	Clinical Flag Totals NE-0 Received Enter Cycle; Err. 0 VI-0 Q-0	Coding Flag Totals CU = 0 CL = 0 CL = 0		
Tan Davey (to:dev3=d/4) Walldation		Validation Trial (ID-MH-2002 05 100 nsor pharma company 1 1 1 1 1 ect primary indication 1	frial phase 111 no. 1	Sublevels References Deleted Searches Reports		country usa	